ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
|
|
|
- Sydney Stephens
- 6 years ago
- Views:
Transcription
1 ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
2 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from Novello Ann Oncol 2016
3 OUTLINE Besse, Ann Oncol 14 3
4 Level of Evidence (LOE) scale Strength of recommendation (SOR) scale Besse, Ann Oncol 14
5 OUTLINE - 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies
6 Meta-analysis Chemo. vs BSC Overall Survival N= trials 9 with platin. 1 yr absolute benefit : 9% (20% to 29%). HR=0,77 [0,71-0,83] p=0,0001 NSCLC Meta-Analyses Collaborative Group JCO 08
7 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies
8 Retrospective analysis of the British Columbia Cancer Registry Immediate CT 8 weeks Referred to a medical oncologist n= 694 Immediate chemo n= 319 (46%) Watch and wait n= 166 (24%) Best supportive care n= 209 (30%) Received chemo n= 50 (30%) Still on watch and wait n= 37 (22%) Missed opportunity for chemo n= 72 (43%) Lost to follow-up n=7 (4%) FUI = 70 days FUI = 25 days Patient choice (n=20) No progression (n=13) Asymptomatic (n=3) Patient Moved (n=1) Declining ECOG (n=36) Patient died (n=35) Asymptomatic (n=1) Comorbid Illness (n=1) Noonan, WCLC 2013
9 Retrospective analysis of the British Columbia Cancer Registry Immediate CT 8 weeks Referred to a medical oncologist n= 694 Immediate chemo n= 319 (46%) Watch and wait n= 166 (24%) Best supportive care n= 209 (30%) Received chemo n= 50 (30%) Still on watch and wait n= 37 (22%) Missed opportunity for chemo n= 72 (43%) Lost to follow-up n=7 (4%) Median Follow-up interval (FUI) = 22 days FUI = 70 days FUI = 25 days Patient choice (n=20) No progression (n=13) Asymptomatic (n=3) Patient Moved (n=1) Declining ECOG (n=36) Patient died (n=35) Asymptomatic (n=1) Comorbid Illness (n=1) Noonan, WCLC 2013
10 Overall Survival of Upfront CT versus WW Populations mos 95% CI -- Upfront Chemo WW-chemo WW-missed CPH Model Covariates: Sex (%) Male Female Hazard Ratio for death (95% CI) 1.00 p-value 0.86 ( ) 0.16 Log-rank p-value< Age 0.99 ( ) 0.24 ECOG PS ( ) Treatment Upfront CT WW-chemo WW-missed ( ) 2.23 ( ) 0.93 < Noonan, WCLC 2013
11 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies Recommendation: The administration of first-line chemotherapy should be offered at diagnosis to asymptomatic patients with metastatic NSCLC. (B, III) Besse, Ann Oncol 14
12 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies
13 Cisplatin or carboplatin? CISCA Response CIS 30 % CARBO 24% OR = 1.37 IC 95% = P <.001 Survival HR = 1.07 IC 95% = 0.99 to 1.15 P =.100 Carbo Cis Survival benefit for 3rd generation combo Ardizzoni JNCI 2007
14 Cisplatin: dose Goffin, JTO
15 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies Recommendations: - Cisplatin should be used in fit patients with PS 0 1 who have adequate organ function. (B, I) - Cisplatin at 75 mg/m² q3wks should be used with 3rd-generation drugs. (B, V) Besse, Ann Oncol 14
16 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies
17 Platinum-based Doublets for NSCLC North American Experience (SWOG + ECOG) n RO MS (m) S 1 an SWOG Cisplatine + Vinorelbine % 8 33% Paclitaxel + Carboplatine % 8 36% ECOG Paclitaxel + Carboplatine % 8 34% Gemcitabine + Cisplatine % 8 36% Paclitaxel + Cisplatine % 8 31% Docetaxel + Cisplatine % % Kelly et al., JCO 01,; Schiller et. al., NEJM 02
18 Platinum-based Doublets for NSCLC North American Experience (SWOG + ECOG) Schiller et. al., NEJM 02
19 Classification Characteristics 1 Non-squamous Squamous Histological classification of NSCLC Adenocarcinoma (AC) 30 50%* Large cell carcinoma 10%* Malignant epithelial tumors with glandular differentiation IASLC classification of invasive AC: 2 Lepidic, acinar, papillary, micropapillary, or solid pattern predominant Variants: invasive mucinous AC, colloid, fetal, and enteric Involves large cells (subtypes are giant cell, clear cell) with large nuclei No evidence of squamous or glandular differentiation Squamous cell carcinoma 30% Involves cells of the squamous epithelium Two variants of clinicopathologic significance 3 Papillary variant Basaloid variant *Image from Image from Other less common subtypes of non-squamous NSCLC include adenosquamous carcinoma and sarcomatoid carcinoma Langer CJ, et al. J Clin Oncol 2010;28: ; 2. Travis WD, et al. J Thorac Oncol 2011;4: ; 3. WHO 2004.
20 Pemetrexed vs gemcitabine (+CDDP) Pemetrexed 500 mg/m² j 1 Cisplatin 75 mg/m² j 1 Adenocarcinoma + LCC pemetrexed better SCC Gemcitabine better Scagliotti JCO 2008
21 Pemetrexed vs gemcitabine (+CDDP) Only 13.4% pts crossed over to pemetrexed! Post-treatment 56.1% of gem/cis Pem 13.4% Gem 8.6% Docetaxel 27.6% EGFR TKI 22.5% 52.6% of pem/cis Pem 3.5% Gem 16.7% Docetaxel 25.4% EGFR TKI 24.9% Scagliotti JCO 2008
22 Pemetrexed vs placebo after 4 cycles pemetrexed/cisplatin PFS OS OS maintenance pemetrexed: 13.9 months 22 Paz-Ares JCO 2013
![[CI 95%] 0.98 [0.85-1.](/docs-images/76/74017011/images/23-2.jpg "14], P=0.")
23 IFCT-GFPC-1101 Overall survival Adjusted HR*, [CI 95%] 0.98 [ ], P=0.81 Perol ASCO 2016
24 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies Recommendation: There is no single platinum-based doublet standard chemotherapy. Pemetrexed-based doublets are restricted to non-squamous NSCLC. (A, I) Besse, Ann Oncol 14
25 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies
26 Optimal duration of chemotherapy First line registration trials PFS: 4 vs 6 cycles of cisplatin-based CT Docetaxel ; TAX 326 Bevacizumab ; ECOG, AVAIL Pemetrexed ; Scagliotti Non progressive Patients after 2 cycles Polo, Ann Oncol 13 - Park et al JCO 07 26
27 3-4 cycles vs. More Overall survival PFS; HR = 0.75; 95% CI, 0.69 to 0.81; P = OS ; HR = 0.92; 95% CI, 0.86 to 0.99; P =0.03). OS 3r generation vs old; (HR=0.70 interaction v 0.92 interaction; P =0.003). Sooc JCO
28 Pemetrexed vs placebo after 4 cycles pemetrexed/cisplatin PFS OS OS maintenance pemetrexed: 13.9 months 28 Paz-Ares JCO 2013
29 Strategy made in Pharmas Control ARM 6X GEM CIS 4X PEM CIS Exp ARM 6X PEM CIS 4X PEM CIS then PEM 29
30 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Recommendation: - 4 cycles of chemotherapy is standard. (A, I) - Continuation of a doublet regimen beyond 4 cycles may be considered in selected, non progressing pts (C, I) Besse, Ann Oncol 14
31 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies
32 Miles Study: Results Gridelli J Natl Cancer Inst. 2003
33
34 Weekly paclitaxel combined with monthly carboplatin versus single agent therapy in patients aged 70 to 89 : IFCT-0501 NSCLC Stage III-IV Age years PS 0-2 n = 451 R A N D O M Vinorelbine or Gemcitabine* Carboplatin + paclitaxel Erlotinib 150 mg/d Phase III study Stratification by centre, PS 0-1 vs. 2, age 80 vs. >80 and stage III vs. IV *Choice of the center at the beginning of the study Quoix, ASCO 2010
35 First-line Treatment V V V V V V V V V V ARM A G G G G G G G G G G WEEKS ARM B C P P P C P P P C P P P C P P P EVALUATION V : Vinorelbine : 30 mg/m 2 G : Gemcitabine : 1150 mg/m 2 C : Carboplatin : AUC 6 P : Paclitaxel : 90 mg/m 2 Choice of the center Quoix, ASCO 2010
36 Overall survival (Primary Objective) MST = 10.3 months Doublet (95% CI ) MST = 6.2 months Single (95% agent CI ) HR= 0.64 ( ); p= Quoix, The Lancet 2011
37 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Recommendation: - Platinum-based chemotherapy is preferred in fit elderly patients with PS 0 1 and adequate organ function. - Single-agent thirdgeneration drugs are preferred in unfit elderly patients. (B, I) Besse, Ann Oncol 14
38 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies
39 Meta-analysis Chemo. vs BSC Overall Survival N= trials 9 with platin. 1 yr absolute benefit : 9% (20% to 29%). HR=0,77 [0,71-0,83] p=0,0001 NSCLC Meta-Analyses Collaborative Group JCO 08
40 Survival by Patient Subgroup [no. events/no. entered] SC + CT SC alone Hazard Ratio (Fixed) PS Protocol Analysis Good 946/ /969 Poor 298/ /284 Interaction p=0.536 PS Exploratory Analysis 0 (100-90%) 301/ /290 1 (80-70%) 645/ / ( 60%) 298/ /284 Trend p= SC + CT better SC alone better NSCLC Meta-Analyses Collaborative Group JCO 08
41 Pemetrexed vs. Pemetrexedcarboplatin in PS2 pts PFS CP months (95% Doublet CI ) P months (95% CI Single ) agent HR = 0.46; 95% CI, 0.35 to 0.63 P< OS (Primary endpoint) CP months (95% Doublet CI ) P months (95% CI Single ) agent HR = 0.62; 95% CI, 0.46 to 0.83 P= cycles, n=201 zukin JCO 13 41
42 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Antiangiogenic? Other strategies Recommendation: Platin-based combinations are preferred over singleagent chemotherapy. (B, I) Besse, Ann Oncol 14
43 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Anti-angiogenic? Other strategies
44 Bevacizumab Non squamous NSCLC Chemo Naive Stage IIIB-IV ECOG PS 0 1 INR <1,5 No history of bleeding or TEE No brain mets Sandler NEJM 2006
45 Paclitaxel Carboplatin - Bevacizumab Population Non squamous NSCLC Chemo Naive Stage IIIB-IV Paclitaxel (200mg/m², d1) + Carboplatin (AUC 6, J1) d1=d21 6 cycles 444 patients Paclitaxel (200mg/m², d1) + Carboplatine (AUC 6, d1) + Bevacizumab (15mg/kg, d1) d1=d21 6 cycles + maintenance bvz 434 patients Sandler NEJM 2006
46 Probabilité Paclitaxel Carboplatine - Bevacizumab OS 12 mo 24 mo PCB 51.9% 22.1% 1,0 0,8 0,6 PC 43.7% 16.9% HR: 0.77 ( ) p=0.007 Median: 12.5 mo vs 10.2 mo 0,4 0, mois Sandler NEJM 2006
47 Bevacizumab Pooled Analysis for PFS - Non SCC NSCLC (toxic in SCC) or 15 mg/kg q3w - CT + bevacizumab then bevacizumab maintenance Soria Ann Oncol 13
48 AVAiL: Ph III Cis/Gem +/- Bevacizumab +/- bevacizumab 7.5 mg/kg +/- bevacizumab 15 mg/kg No formal comparison of the doses But does dose matter?
49 BO21015 (ABIGAIL) Previously untreated, stage IIIB, IV nonsquamous NSCLC (n=300) Stratified by stage, gender, PS, chemotherapy Bevacizumab 7.5mg/kg q3w + up to six 21-day cycles of CG or CP (n=150) Bevacizumab 15mg/kg q3w + up to six 21-day cycles of CG or CP (n=150) P D No cross-over permitted P D Primary endpoint: exploration of correlation between candidate biomarkers and overall response rate to chemotherapy plus bevacizumab Carboplatin/Gemcitabine (CG) or Carboplatin/Paclitaxel (CP) Chemotherapy regimen was not randomly allocated but was chosen by the Investigator Mok J Thorac Oncol 2014
50 BO21015 (ABIGAIL) Only LOW baseline plasma VEGF-A correlated with PFS (p=0.002) and OS (p=0.004) 7.5 mg/kg vs. 15 mg/kg, HR 1.01, 95% CI: ~60% of patients received CG Mok J Thorac Oncol 2014
51 BRAIN: phase II trial of bevacizumab in patients with CNS metastases 6 cycles Stage IV non-squamous NSCLC with untreated asymptomatic brain metastases (n=66) n=66 Bevacizumab 15 mg/kg q3w + paclitaxel + carboplatin Bevacizumab 15 mg/kg q3w Besse Clin Can Res 2015
52 AvaALL phase III: BVZ beyond PD Primary endpoint: OS Courtesy of J.Remon Bennouna ASCO 2017
53 Negative phase III trials in NSCLC with anti-angiogenic agents ( ) Compound Mechanism of action N trials N End Point Thalidomide Anti-angiogenic OS Cediranib VEGFR TKI OS Vandetanib Multikinase TKI PFS/OS AE-941 Anti-angiogenic OS Sorafenib Multikinase TKI OS Motesanib Multikinase TKI OS Sunitinib Multikinase TKI OS Aflibercet VEGF/PlGF OS Total
54 OUTLINE 1st line: platinum based CT When to start? Cisplatin or carboplatin? A best doublet? How many cycles? For elderly patients? For PS2? Anti-angiogenic? Other strategies
55 Cetuximab, meta-analysis Cetuximab + CT improved OS (HR 0.88, p=0.009) PFS (HR 0.90, p=0.045) and RR (ORR 1,46, p< 0.001) Greatest survival benefit in Squamous (HR 0.77, 95% CI ) Courtesy of J.Remon Pujol Lung Cancer 2014
56 SQUIRE trial: Necitumumab in Squamous First-line Stage IV Squamous NSCLC 3,4 ECOG PS 0-2 R Neci + Gem-Cis q3w (N=545) Necitumumab 800 mg D1, D8 Gemcitabine 1250 mg/m², D1, D8 Cisplatin 75 mg/m², D1 Maximum of 6 cycles CR PR SD PD Neci q3w 800 mg D1, D8 PD Gem-Cis q3w (N=548) Gemcitabine 1250 mg/m², D1, D8 Cisplatin 75 mg/m², D1 PD Primary Endpoint: OS Randomization stratified by: ECOG PS (0-1 vs. 2) and geographic region (North America, Europe, and Australia; vs. South America, South Africa, and India; vs. Eastern Asia) Courtesy of J.Remon Thatcher- Lancet Oncol 2015
57 SQUIRE trial: Necitumumab in Squamous OS 1y OS: 48% 1y OS:43% 2y OS: 20% 2y OS: 17% Courtesy of J.Remon Thatcher- Lancet Oncol 2015
58 Nab-paclitaxel in NSCLC Nab-Paclitaxel 100 mg/m 2 QW CBDCA (AUC=6) Q3W First-line Stage IV ECOG PS 0-2 EndPoint: ORR R N=1052 Maximum of 6 cycles Paclitaxel 100 mg/m 2 QW CBDCA (AUC=6) Q3W Courtesy of J.Remon Socinski JCO 2012 * Socinski Ann Oncol 2013
59 New standard? Nab-Paclitaxel SQUIRE Nab-Paclitaxel Carboplatin Paclitaxel CBDCA Necitumumab Cis/Gem Placebo Cis/Gem N (Squamous) ORR (%) 41 24* PFS (mo) OS (mo) * G3-5 AE (%) * Statistically significant Courtesy of J.Remon Socinski JCO 2012 * Thatcher Lancet Oncol 2015
60 First-Line IO + CT Ph.II Pem. Carbo. +/- PEMBROLIZUMAB KEYNOTE 021 Ph.III Pacli. Carbo. Bev. +/- ATEZOLIZUMAB IMPOWER 150 Press release - Jan, 16th 2018 Ph. III KEYNOTE 189 Positive for PFS and OS All comers All comers Langer Lancet Oncol 2016 * Borghaei ESMO 2017 * Langer WCLC 2017 Reck M, et al. ESMO IO Meeting 2017
61 1st line metastatic NSCLC Treatment options Gemcitabine 1250 mg/m² d 1, 8 q3w Cisplatin 80 mg/m² d 1 All histologies Vinorelbine 25 mg/m² d 1, 8, 15, 22 Cisplatin 100 mg/m² d 1 d1=d28 Historical design, all histologies Pemetrexed 500 mg/m² d1 Cisplatin 75 mg/m² d1 d1=d21 Non squamous NSCLC +/- bevacizumab if non SCC. THÈME 7,5 mg/kg DU DIAPORAMA or 15 mg/kg d1=d21
62 1st line metastatic NSCLC Treatment options Docetaxel 75 mg/m² d 1 Cisplatin 75 mg/m² d 1 Paclitaxel 135 mg/m²(24 h) d 1 Cisplatin 75 mg/m² d 2 Paclitaxel 225 mg/m²(3 h) d 1 Carboplatin AUC 6 d 1 d1=d21 d1=d21 d1=d21 All histologies, induce alopecia +/- bevacizumab if non SCC. THÈME 7,5 mg/kg DU DIAPORAMA or 15 mg/kg d1=d21
63 WE NEED NEW CHEMO! 63
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
Angiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
Maintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
Squamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
VEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
Practice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
NSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
Histology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
Second-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
The road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
Maintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
Medical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
Immunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
Nivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
LUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
Treatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
Histology in the Decision-making Process
Histology in the Decision-making Process Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Lung Cancer Four Main Histological Subtypes
Non-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
Treatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
Maintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
Immune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
INMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
Carcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona
Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% 1998-1999 2000-2003 2004-2007
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
Thoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
Recent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
Treatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
Personalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
INNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
in combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
Lung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
Alessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis
Original Article First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis Lisa M. Hess, Amy M. DeLozier, Fanni Natanegara,
Recent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
Algoritmo de tratamiento del CNMP escamoso. Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla
Algoritmo de tratamiento del CNMP escamoso Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla Agenda CNMP escamoso vs no escamoso: diferencias? Opciones de tratamiento 1L Opciones de tratamiento
Second-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
Sao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
Quale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
Largos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
Heather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
Stage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
Incorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
ACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
Targeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
Personalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
Is there a role for maintenance therapy in advanced non-small-cell lung cancer?
Review Is there a role for maintenance therapy in advanced non-small-cell lung cancer? Cesare Gridelli*1, Paolo Maione1, Antonio Rossi1, Clorinda Schettino1, Maria Anna Bareschino1, Paola Claudia Sacco1,
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
Patient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
ASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
Background. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
SURGICAL GRAND ROUNDS
SURGICAL GRAND ROUNDS David H. Harpole, Jr., M.D. New Options for Achieving Individualized Approaches to Non-small Cell Lung Cancer Management Dr. Harpole has financial relationships with the following
Malignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Clinical Medicine Insights: Oncology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?